ArticleFuture oncology (London, England)2023
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Article in Future oncology (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review.Oncology research · 2025Pooled it
- Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2024Trial
- Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023).The oncologist · 2026Article
- Progress in management of advanced clear-cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.JCO oncology practice · 2026Article
- The clinical landscape of HIF2α inhibitors in oncology.Nature reviews. Clinical oncology · 2026Review
- Efficacy and Safety of Lenvatinib Plus Everolimus in Metastatic Renal Cell Carcinoma after Immune Checkpoint and VEGFR Tyrosine Kinase Inhibitors Treatment.Cancer research and treatment · 2026Article
- Durable benefit in a crowded frontline landscape: final results for nivolumab-cabozantinib in metastatic renal cell carcinoma.Translational andrology and urology · 2026Article
- Von Hippel-Lindau disease: pathophysiological and clinical advances.Familial cancer · 2026Review
- Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial.Translational andrology and urology · 2026Article
- First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.Cancer chemotherapy and pharmacology · 2026Review
- Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma.Frontiers in oncology · 2026Review
- A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors.Frontiers in immunology · 2026Article
- Mapping therapy-responsive immune ecotypes in clear cell renal cell carcinoma through integrative omics.Frontiers in immunology · 2026Review
- Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group.Cancer management and research · 2026Article
- Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives.Clinical and experimental medicine · 2025Review
- Long-term HIF-2α inhibition in von Hippel-Lindau disease: insights from LITESPARK-004.Translational andrology and urology · 2025Article
- A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 5 countries.
Funding
Abstract
The first-in-class, small molecule HIF-2α inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2α also regulates VEGF expression and is involved in resistance to anti-VEGF therapy. This study describes the rationale and design for a randomized, phase III study evaluating efficacy and safety of belzutifan plus the tyrosine kinase inhibitor (TKI) lenvatinib versus the TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second-line setting or as adjuvant therapy. Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.